Apomorphine Monotherapy for Parkinson's Disease: A Neglected Option?

1AP-HP, Salpetriere Hospital, DMU Neuroscience 6, Paris, France 2University Lille, Lille Neuroscience & Cognition, Team DVCD, INSERM UMRS_1172, CHU Lille, Department of Medical Pharmacology, Expert Center of Parkinson’s Disease, LICEND COEN Center, NS-Park/FCRIN Network, France 3Sorbonne University, Paris Brain Institute, INSERM, CNRS, Paris, France LETTER TO THE EDITOR https://doi.org/10.14802/jmd.23057 / J Mov Disord 2023;16(3):328-330 pISSN 2005-940X / eISSN 2093-4939